3
Announcements
Trials
Browse
Landscape
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma
1
Iron Overload
1
Hemoglobinopathies
1
Interventions
Rituximab
20
Cyclophosphamide
18
Etoposide
11
Vincristine
10
Doxorubicin
10
fludarabine phosphate
9
Prednisone
9
Filgrastim
9
Radiotherapy
8
Peripheral Blood Stem Cell Transplantation
8
Cytarabine
8
Methotrexate
7
Melphalan
7
Dexamethasone
6
fludarabine
4
Cyclosporine
4
Antilymphocyte Serum
4
duvelisib
3
belinostat
3
Thiotepa
3
Tacrolimus
3
Nivolumab
3
Mycophenolic Acid
3
Lenalidomide
3
Ifosfamide
3
Gemcitabine
3
Carmustine
3
Busulfan
3
Alemtuzumab
3
sargramostim
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Lymphoma
×
Continuous Glucose Monitoring
×
Clear all
NCT03141398
2017-07-26
CGMs
Hamad Medical Corporation
Withdrawn